Introduction
Gliomas are the most common primary tumors of the brain, with an incidence in the United States of nearly 20-25 000 new cases per year (Kleihues and Cavenee, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith and Jenkins, 2000; Smith et al., 2001; Kapoor and O'Rourke, 2003) . Half of all gliomas, including the anaplastic astrocytomas (AAs) and glioblastoma multiforme (GBM), exhibit aggressive behavior. GBMs, in particular, are clinically and pathologically malignant. Patients with GBM have a poor prognosis, with a median survival of 1 year with aggressive therapy; fewer than 5% of patients will survive 5 years (Kleihues and Cavenee, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001) . In spite of its low incidence, deaths from GBMs account for 2.5% of all cancer deaths each year in the US (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001; Kapoor and O'Rourke, 2003) . At present, the mainstays of treatment include surgical resection, radiation, and chemotherapy. Once adjuvant therapy is completed, GBMs generally recur at the margins of surgical resection and tend to be more aggressive than at initial presentation. At this stage, most therapy is palliative (Kleihues and Cavenee, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001) .
Current models of gliomagenesis suggest that two alternative pathways exist (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001) . In the first, progression from a World Health Organization (WHO) low-grade to a high-grade glioma involves the serial accumulation of genetic alterations that inactivate tumor suppressor genes -such as p53, p16, RB, and PTEN -or activate oncogenes such as MDM2, CDKs 4 and 6 (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001) . In the second model, epithelial growth factor receptor (EGFR) gene amplifications, often combined with gene rearrangements that lead to a constitutively active, truncated receptor, occur in high-grade gliomas that possess wildtype p53 (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001) . These 'primary' gliomas are thought to arise de novo, especially in older patients. Alternatively, gliomas may be thought to arise along two competing paths: one, altered growth factor signaling (for example, activation of the EGFR-Ras-MAPK, PDGFR, or Akt pathways), which leads to cell proliferation, cell cycle progression, and apoptosis inhibition; and two, dysregulation of cell cycle arrest, either through p16 ink4a control of Rb or p14 arf modulation of MDM2 and p53 (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001; Kapoor and O'Rourke, 2003) . Clinically, these two models are made manifest as well: de novo GBMS typically arise in older individuals (mean age, 55 years) and appear to follow a more aggressive pattern than secondary or progressive GBMs, which arise several years after the first manifestation of a lower grade tumor in younger patients (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001; Kapoor and O'Rourke, 2003) . In general, whether GBMs have arisen de novo or by progression from a low-grade astrocytoma, mutations or alterations in the PTEN gene appear, in as many as 50% of tumors, to be a final, common denominator insuring rapid proliferation, resistance to apoptosis, and resistance to chemotherapeutic and radiotherapeutic modalities (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001; Kapoor and O'Rourke, 2003) . Nonetheless, while genetic abnormalities have been useful in describing the two distinct clinical entities in GBM, it remains unclear whether the predictive value of genetic dissection relates as much to the genetic pathways described or whether secondary GBMs tend to arise in younger, healthier patients who may be more capable of tolerating aggressive, multimodality therapy (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001) .
Our study was designed to see if these genetic and clinical distinctions could be identified at the global protein expression level. We employed selective tissue microdissection to obtain pure populations of tumor cells, which we studied using two-dimensional protein gel electrophoresis (2-DGE) and protein sequencing of select target proteins expressed uniquely in different tumor types, to identify two categories of GBMs.
Results
Clinical information about the patients and genetic mutational information about the tumors are collected in Table 1 . There were 13 patients with GBMs (WHO Classification grade IV tumors) studied, of which six tumors were de novo in origin, while seven tumors arose from a lower grade glial neoplasm. Treatments, including surgery, chemotherapy, and radiation therapy; time to recurrence or progression; and overall survival and current status are recorded as well (Table 1) .
Tumors were microdissected and pure populations of tumor cells were analysed in a blinded manner, independent of clinical or genetic status. 2-DGE distinguished two populations of tumors, those that arose de novo and those that progressed from a lower grade tumor (Figure 1 ). In addition, the 2-DGE method was precise and reproducible, since in all instances, the two-dimensional gels from different patients segregated with the appropriate type of tumor, de novo or progression, as demonstrated in Figure 2 for three patients from both groups. Furthermore, protein patterns from multiple, disparate sites within the same tumor (from two to three tumor samples in nine patients, obtained at distances at least 3 cm apart from one another, for a total of 23 tumor specimens examined, 11 from primary GBMs, and 12 from progression GBM samples) were reproducible and homogeneous, as illustrated in Figure 2c . There were no significant differences in the protein patterns observed for the secondary GBMs, whether they arose from a grade II or a grade III tumor, or whether they were treated previously or not. In addition, two identical proteins expressed in each tumor type (n ¼ 6 primary, n ¼ 7 secondary GBMs) were isolated from the gels, sequenced, and confirmed to be identical, which further confirms the reliability of this method (data not shown). EGFR staining was evaluated to confirm differential protein expression: five of six primary GBMs had 2 þ staining and one patient (pt #3, who had no EGFR or PTEN alterations detected genetically) had 1 þ , or normal staining; six of seven secondary GBMs had absent staining (0) and one patient (patient #1) had trace staining in only a few (o5%), scattered tumor cells (Table 1) .
Using MS/MS techniques, we isolated and sequenced 11 proteins that were uniquely expressed in either the primary or the secondary GBMs (Table 2 ), but not in both; these proteins served to distinguish the two types of proteomic patterns. The proteins were identified after mass spectrometric analysis of two or more unique peptide sequences within that protein, each of whose probability scores met or exceeded the threshold (Po0.05) for statistical significance. Analysis of primary GBMs showed expression of five unique proteins that are involved in signal transduction (EGFR), cell migration (tenascin-X), cell glycolytic metabolic pathways (enolase 1), and in cell cycle control (centrosomeassociated protein 350). A final protein, whose function remains unknown, is distinctive to primary GBMs. In contrast, secondary GBMs did not express those proteins but rather several other proteins involved in cell metabolism (DUOX2), DNA repair (ERCC6), general transcription regulation (hnRNP A3), and the Wnt-b-catenin system (Wnt11, cadherin-related tumor suppressor homolog precursor). These proteins were exclusively expressed in one group of GBMs, but not the other, in all cases (n ¼ 23 samples from 13 patients) studied. Western blotting of tumors from both types was carried out using antibodies to EGFR and hnRNP A3, with expression of the former in primary GBMs and the latter in the secondary GBMs, confirming the MS/MS findings (Table 1 and Figure 3 ). Figure 1 Proteomic patterns of primary and secondary GBM. Left, a representative two-dimensional gel electrophoresis panel for one of the primary GBMs. The bottom panel is an enlargement of the area noted in the upper figure. Right, the two-dimensional gel electrophoresis protein expression pattern for a secondary GBM, with the enlargement, bottom, depicting the same area as in the primary GBM. Proteins encircled in green are common to both types of GBMs, those in blue are expressed uniquely by primary GBMs, and those expressed uniquely by secondary GBMs are circled in red Figure 2 Reproducibility of the method. (a, b) Two-dimensional gel electrophoretic panels for three primary (top, a) and three secondary GBMs (middle, b) are demonstrated, showing intratumoral type reproducibility. (b) Top two tumors were GBMs that arose from WHO grade II tumors, one of which had been treated with radiation (top, patient #6) and one of which had not (middle, patient #7); the bottom panel is from a patient whose GBM arose from a grade III tumor (patient #8). Proteins unique for primary tumors are circled with blue and for secondary tumors, in red. (c) (bottom panels) ate intra-tumoral homogeneity. Two-dimensional gel electrophoretic panels from three separate sites within one primary GBM (patient #3) are illustrated. The lower panels are enlargements of the area noted in the upper figure. Red circles mark identical, low-abundance proteins found in all three sites The probability that one protein would be found in all six primary GBMs and none of the seven secondary tumors (and vice versa) was calculated using the MannWhitney test and was statistically significant (P ¼ 0.0012). Finally, statistical evaluation suggested that this method of identification and discrimination was robust, as the probability that 11 or more proteins would be distributed randomly, but uniquely, between the two subtypes is expressed by the binomial probability distribution as approximately 5.5 Â 10 À16 .
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Classically, GBM has been stratified into one of two forms, primary or de novo tumors and secondary or progressive tumors that arise from lower-grade gliomas (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001; Kapoor and O'Rourke, 2003) . In general, the former tend to occur in older patients, to arise suddenly, and to pursue an aggressive course; on the other hand, secondary GBMs tend to occur in younger patients, evolve out of a lower grade glial tumor, such as an astrocytoma, after several years latency, but then to behave essentially as ruthlessly as primary GBMs (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001; Kapoor and O'Rourke, 2003) . The only difference in outcome between these two groups may be that younger patients, in whom secondary GBMs may be more likely, tend to have better performance status at the time of GBM presentation and to tolerate surgery and adjuvant therapies more robustly (Kleihues and Cavenee, 2000; Tortosa et al., 2000; Simmons et al., 2001; Smith et al., 2001; Batchelor et al., 2004) . Nonetheless, a diagnosis of GBM, no matter the clinical presentation, carries with it a grave prognosis, with a 5-year survival rate of 5% or less (Kleihues and Cavenee, 2000; Lacroix et al., 2001; Simmons et al., 2001; Smith et al., 2001; van den Boom et al., 2003) . The clinical picture of two different origins has been identified at the genetic level as well (Kleihues and Cavenee, 2000; Smith and Jenkins, 2000; Tortosa et al., 2000; Smith et al., 2001; Batchelor et al, 2004) . In general, GBMs that arise from lower grade tumors acquire alterations in the p53 tumor suppressor gene early in their development; over time, as lower grade tumors become more malignant, they accumulate additional genetic defects in a variety of genes, such as p16, Rb (retinoblastoma), DCC (deleted in colon cancer), and PTEN. De novo GBMs less commonly express these mutations in the face of the more dominant effects of alterations in the EGFR, such as amplification or a truncated constitutively active receptor, all of which lead to EGFR overexpression and activation of the downstream EGFR-Ras-MAPK signaling cascade (Smith and Jenkins, 2000; Simmons et al., 2001; Smith et al., 2001; Kapoor and O'Rourke, 2003) .
Using selective tissue microdissection to procure a pure population of tumor cells, we used two-dimensional gel electrophoresis to detect these two subtypes of GBM and to confirm these subtypes at the protein level. 2-DGE can reproducibly detect specific patterns of protein expression that correspond to the de novo and secondary GBM types, as defined both clinically and genetically. These patterns are homogeneous between tumors as well as among disparate sites (separated by more than 3 cm) within the same tumor. In addition, this method permits identification, on a large scale, of unique or subtle differences that routine pathological or immunohistochemical methods may not identify or predict. Small alterations in individual protein patterns can be identified by 2-DGE (Figure 1 ) and, more importantly, can provide a significant amount of information quickly about protein differences among tumors, which can allow identification of new or unsuspected mechanisms, diagnostic methods or tools, and potential therapeutic targets.
In total, 11 proteins uniquely expressed in one of the two types of GBMs were sequenced and identified (see results and Table 2 ). Five of these proteins (tenascin-X precursor, enolase 1, centrosome-associated protein 350, EGFR, and a previously unnamed protein) were expressed only by primary GBMs. In the primary GBMs, one protein, EGFR, was identified by 2-DGE and confirmed by immunohistochemistry and Western blotting, which highlights the central role that the EGFR-Ras-MAPK pathway plays in the genesis of these tumors (Bischoff and Plowman, 1999; Giles et al., 2003; Veeman et al., 2003; PubMed, 2004) . By contrast, of the six proteins identified in specifically in secondary GBMs, one is associated with DNA repair (three of seven of the progressive tumors had received radiation prior to tissue collection), one with oxidative stress (DUOX2) and cell proliferation, another with transcriptional regulation (hnRNP A3), and a fourth with cell migration and invasion (the ADAMTS-19 precursor) Khatua et al, 2003; Nutt et al., 2003; van den Boom et al., 2003) .
Interestingly, two proteins that appear to be involved in the Wnt-b-catenin system (Wnt11 and the cadherinrelated tumor suppressor homolog precursor) were identified only in secondary GBMs. Wnt proteins belong to a large family of secreted glycoproteins, preserved from Drosophila to man, that plays a key role in cell fate determination, asymmetric cell division, and central Figure 3 Western blot analysis of proteins identified by proteomic profiling. Western blotting analysis of primary (n ¼ 4) and secondary (n ¼ 5) glioblastomas was performed using antibodies to EGFR and to hnRNP A3, respectively. b-Actin served as a control Identification of subtypes of GBM M Furuta et al nervous system patterning (Giles et al., 2003; PubMed, 2004) . Activation of the Wnt signaling cascade facilitates movement of b-catenin to the nucleus, where it is a powerful transactivator. Activating mutations of the Wnt pathway have been identified in a variety of human cancers, including some medulloblastomas (Giles et al., 2003) . In addition, the Wnt pathway may be activated independently of b-catenin, which may explain the presence of the cadherin-related tumor suppressor homolog precursor (Veeman et al., 2003) . The known or potential roles of these proteins in gliomagenesis are outlined in Table 2 . Finally, we also identified a novel protein, whose function is currently unknown, but which is specifically expressed in primary GBMs. Methods such as ours raise the potential to identify new protein targets for diagnosis and therapy. Advantages of the 2-DGE method, compared with other protein-based techniques like MALDI-MS or SELDI-MS, is that the protein 'spot' can be identified and sequenced directly. While MALDI or SELDI are more tractable for running large-scale experiments of numerous samples, selective tissue microdissection and 2-DGE requires less in the way of instrumentation, expense, up-keep, and personnel. There are some potential advantages of this method compared with oligonucleotide microarrays, as well. Several recent studies have highlighted the broad utility of microarrays in identifying transcriptional networks or in describing tumor subtypes, both in gliomas and in many other tumors (Kleihues and Ohgaki, 1999; Lal et al., 1999; Sallinen et al., 2000; Rickman et al., 2001; Fuller et al., 2002; Kim et al., 2002; Ramaswamy and Golub, 2002; Godard et al., 2003; Khatua et al., 2003; Mischel et al., 2003; Nutt et al., 2003; Shai et al., 2003; van den Boom et al., 2003) . Like our method, microarrays require downstream confirmation and functional validation (Ramaswamy and Golub, 2002) . Furthermore, it is important to note that with 2-DGE methods such as this one, it can be difficult to identify low-abundance proteins and that special methods may need to be used to isolate membrane-bound proteins or proteins that are very basic or acidic (our pH range was 4-7) (Hanash et al., 2002) . However, with protein identification methods such as 2-DGE, one obtains direct information about the protein or proteins encoded by a gene, as well as translational and post-translational modifications (Ramaswamy and Golub, 2002) . One further, potential disadvantage of microarrays is that they require significant investments in time and equipment, can be technically challenging, and require significant statistical expertise (Hanash et al., 2002; Kim et al., 2002; Ramaswamy and Golub, 2002) . Thus, it appears likely that 2-DGE will serve as a useful adjunct to microarrays and other expression technologies. Additional methods, such as difference gel electrophoresis (DIGE) or isotopecoded affinity tagging (ICAT), may be necessary to explore quantitative and/or differential expression of proteins that are found in both tumor types (Gygi et al., 1999; Hanash et al., 2002) . This was not the goal of this study, whose aim was to identify specific protein expression patterns and to discover individual proteins that were expressed uniquely in one or the other of the two GBM subtypes.
In summary, we have used 2-DGE and protein sequencing to identify proteotypic expression profiles and to discover specific proteins that are uniquely expressed and which distinguish primary GBMs from those that arise secondarily from lower grade gliomas. We show that a relatively small number of proteins can be used to distinguish between these two tumor subtypes in a statistically significant manner. These differences arise in proteins from several different classes, including signal transduction, cell migration and metabolism, DNA repair, and cell cycle control. Several of these proteins have been suspected of playing a role in tumorigenesis in non-CNS tumors, but have not previously been described for gliomas, including members of the Wnt-b catenin family. This method is simple, accurate, and reliable and may prove useful in defining molecular subtypes of GBMs and other gliomas (Vortmeyer et al., 2003) . Additional studies are underway to enhance and expand 2-DGE analysis of a larger spectrum of human gliomas as well as to identify and characterize additional known and suspected peptide/ protein biomarkers. Once identified, characterization of the function and biological role of some of the proteins involved in gliomagenesis may permit their use as diagnostic and prognostic markers as well as therapeutic targets, in predicting response to therapy, and in identifying new molecular targets for therapy.
Materials and methods
Clinical material
Tumor and other normal tissues and blood were collected at the time of surgery. All patients were operated upon by a single surgeon (RJW). Tissue was immediately snap frozen in liquid nitrogen, and stored at À801C until analysed. Total RNA and DNA were extracted from 20 mg of each of the frozen tumor samples using Qiagen RNA/DNA extraction kits (Qiagen, Valencia, CA, USA). DNA from blood samples was purified using Qiamp DNA blood extraction microcolumns (Qiagen). Clinical information was obtained from the patient's chart. Tissues and clinical information were obtained as part of an Institutional Review Board-approved study at Vanderbilt University School of Medicine.
Genetic analysis
Sequencing for p53 and PTEN mutations were performed using a 1 min 951C, 1 min anneal, 1 min 721C pattern; annealing temperatures are 51 below noted melting points or annealing temps, according to the method, and using the primers, described by Smith and Jenkins (2000) .
EGFR expression analysis was carried out by quantitative RT-PCR techniques using appropriate intron spanning primers and radioactive nucleotide labeling, as previously described (Smith and Jenkins, 2000) . In brief, 250 nmol of total RNA from each tumor was used to create cDNA by singlestrand reverse transcription using Superscript reverse transcriptase (Invitrogen, Carlsbad, CA, USA). An average quantitative standard was created by pooling all sample cDNAs. The pooled sample was subjected to 10-35 cycles of PCR with appropriate intron spanning primers for EGFR and GAPDH transcripts in the presence of 1 mCi/ml a-32 P labeled dCTP. A standard amplification curve was created for EGFR and GAPDH transcripts by quantifying radiolabeled PCR product at every second cycle. A range of six cycles was determined to have linear amplification for each primer set in the pooled sample. Each tumor cDNA sample was then amplified in the presence of 1 mCi/ml a-32 P labeled dCTP over the range of six cycles for each primer set, run on a 6% denaturing polyacrylamide gel, and quantified after a 10 h exposure to 32 P phosphor screen. Linearity of PCR amplification over the six cycles was confirmed for each tumor sample and quantification of EGFR mRNA was determined as a ratio of EGFR radiolabeled-PCR product to GAPDH PCR product. All reactions were carried out in triplicate and results were averaged. The following primer sequences were used for PCR amplification of cDNA: EGFR -F (forward): TCTCAG-CAACATGTCGATGG, R (reverse): TCGCACTTCTTA-CACTTGCG, GAPDH -F: GAGCCACATCGCTCAGAC, R: TTCTCCATGGTGGTGAAG.
Single-strand conformation polymorphism (SSCP) analysis was performed as follows. In brief, amplification products were analysed by performing SSCP on a 6% w/v polyacrylimide nondenaturing gel. Equal volumes of PCR product and loading buffer (90% v/v formamide, 1.2 mM EDTA, and 0.2% w/v dyes (bromophenol blue and xylene cyanole FF) were mixed at 941C for 10 min and immediately placed on ice and cooled for 10 min. Samples were resolved by electrophoresis at constant wattage (8 W) for 16 h. After electrophoresis, gels were dried on chromatography paper for 70 min at 801C. Dried gels were exposed on film for 24 h and analysed. DNA were PCR-amplified and gel purified, as described above. Sequencing was performed commercially (Seqwright, Houston, TX, USA).
Immunohistochemistry and Western blotting
EGFR overexpression was confirmed by immunohistochemical staining, in a blinded manner. Cells with no (0) staining were considered to have absent EGFR expression; those with trace (trace) staining to rare, positive tumor cells; tumors with 1 þ staining were considered to have normal levels of EGFR in all or nearly all tumor cells; and those that were 2 þ were considered to have overexpressed EGFR. Overexpression correlated with the results of quantitative RT-PCR. Results are noted in Table 1 . Antibodies for EGFR and hnRNP A3 were obtained from Cell Signaling Technologies (Beverly, MA, USA) and Santa Cruz (Santa Cruz, CA, USA), respectively. Immunoblotting was performed using standard techniques (Ausubel et al., 1999) .
Tissue microdissection and two-dimensional gel electrophoresis
Selective tissue microdissection was performed as follows. From all tumor samples, a single 10-mm-thick section was taken and stained with hematoxylin and eosin for histologic evaluation. A semiquantitative cell count was performed on tumor-rich (490% tumors cells) areas that were not compromised by inflammation, necrosis, or stromal or endothelial proliferation. Subsequently, these areas were subjected to selective tumor dissection from serial sections, as previously described (Zhuang et al., 1995) . We collected approximately 50 000 cells from each sample, which were obtained from one to 10 consecutive sections. Procurement of normal brain, or areas of inflammation, necrosis, hemorrhage, or stromal or vascular proliferation was strictly avoided. Tissue dissection was performed manually on unstained sections to avoid possible heating artifacts induced by laser-assisted technology or chemical artifacts induced by tissue staining (Gottlieb and Chavko, 1987; Palmer-Toy et al., 2000) . Protein content was compared and found equivalent to that derived from 50 000 cultured GBM cells (U87MG).
Microdissected cells were collected into 30 ml of Extraction buffer II containing 8 M urea, 4% (w/v) CHAPS, 40 mM Tris, 0.2% (w/v) Bio-Lyte 4/7, and 2 mM tributyl phosphine (BioRad, Hercules, CA, USA), vigorously vortexed at room temperature for 60 min, and centrifuged in a microcentrifuge at 12 000 r.p.m. for 15 min. The supernatant was combined with 150 ml of rehydration Buffer (Bio-Rad) containing 8 M urea, 2% CHAPS, 50 mM DTT, and 0.2% (w/v) Bio-Lyte 4/7 ampholytes, before isoeletric focusing.
A total of 13 tumors (six primary GBMs and seven secondary GBMs) were analysed by 2-DGE. In nine cases, multiple specimens from larger tumors (from two to three separate biopsy sites in each case), procured at least 3 cm away from one another, were examined, for a total of 23 tumor specimens (11 primary and 12 secondary GBMs) evaluated. Of the secondary GBMs, five were WHO grade II astrocytomas at origin and two were grade III tumors. Four of the seven lowgrade tumors had received no adjuvant chemotherapy or radiation therapy prior to development of the GBM, while three had been treated with radiation, chemotherapy, or both ( Table 1) .
The first dimension of two-dimensional electrophoresis was performed on a Protean IEF System (Bio-Rad) with ReadyStrip IPG strips (pH 4/7, 11 cm) (Bio-Rad) rehydrated with 185 ml of sample for 12 h and subsequently subjected to high voltages at 201C for electric focusing: 250 V for 20 min, 8000 V for 2 h and 30 min, and a final step of 25 000 Vhours. IPG strips were washed in rehydration buffer I containing 6 M urea, 2% SDS, 375 mM Tris-HCl (pH 8.8), 20% glycerol, and 2% (w/v) DTT; and buffer II containing 6 M urea, 2% SDS, 375 mM Tris-HCl (pH 8.8), 20% glycerol, and 2.5% (w/v) iodoacetamide (Bio-Rad), for 10 min each. Criterion Precast Gels (8-16% Tris-HCl, 1.0 mm) (Bio-Rad) were used for the second dimension of protein separation in a Criterion Dodeca cell (Bio-Rad) under a constant voltage of 200 V for 55 min. Silver Stain kit (Bio-Rad) was used to detect protein spots according to the manufacturer's instructions. Methanol and acetic acid needed for fixing gels were purchased from SigmaAldrich (St Louis, MO, USA). Gels were run in duplicate on at least one sample of tumor from each patient to confirm the results of gel electrophoretic patterning.
In-gel digestion
Protein spots of interest were excised from the gel, placed into clean 0.5 ml Eppendorf tubes and stored at À201C. Silverstained spots were de-stained according to Blum et al. (1987) After de-staining, individual protein gel spots were subjected to reduction and alkylation, followed by in situ digestion with trypsin. The resultant peptide mixtures were recovered by sequential extraction and dried to near completion in a vacuum centrifuge, and diluted to 4 ml final volume in 2% CH 3 CN, 0.1% HCO2H, 0.01% TFA, as previously described (Stone and Williams, 1993) .
Mass spectrometry
Peptides from in-gel digests were analysed by Nano-Spray LC-MS/MS. A capillary HPLC system (LC Packings Inc., San Francisco, CA, USA) was interfaced to a QSTAR mass spectrometer (Applied Biosystems, Foster City, CA, USA The chromatograph was developed using a linear gradient from 5% B to 40% B over 20 min. Then, a second linear gradient was applied from 40% B to 95% B in 5 min. The gradient was held at 95% B for 10 min. At the end of the period, the gradient was returned to 5% B in 3 min and was held for 10 min for column equilibration before next injection. The QSTAR was set to iteratively acquire a Positive TOF MS scan at 1 s accumulation time between 400 and 1700m/z followed by informationdependent ACQUISITION (IDA). MS/MS scans at 5 s accumulation time between 50 and 2500m/z of the three most abundant ions from the preceding MS scan. An enhanced all collision energy for collision-induced dissociation was set to 16.7% at 30, 75, 150, 300 and 600 amu and to 16.5% at 1200 amu. The IDA experiment surveys ions, which exceeds 10 counts with charge state from 2 to 5. The former target ions were excluded for 45 s.
Protein identification
Unprocessed data files containing MS/MS spectra were submitted to the Mascot search engine (MatrixScience Ltd, London, UK) for database searching using the Mascot daemon. Mascot compares the mass values of observed product ions with the mass values calculated for theoretical product ions from peptide sequences present in a specified genomic database. From this comparison, a probability-based score is calculated, which reflects the statistical significance of the match between the product ion spectrum and the sequences contained in a database (Perkins et al., 1999) . The SwissProtTrmbl database was searched using Homo sapiens as a taxonomic restrictor (Boeckmann et al., 2003) .
While it is conceptually possible to identify a protein based on a single peptide, we considered single peptide identification insufficient for protein identification due to the 'golden match standard.' Briefly, it is possible that a peptide sequence is deemed correct (i.e. the top match) based on statistical and/or subjective criteria and not actually be correct due to incompleteness of genomic databases (Moore et al., 2002) . For this study, we required a minimum of two unique peptides at disparate sites within a protein to be the minimum for a positive identification; in other words, the protein sequence was identified only after mass spectrometric analysis of two or more unique peptides, each of whose probability scores met or exceeded the threshold (Po0.05) for statistical significance. Proteins and associations with normal and diseases states were checked and verified on the NCBI protein and Online Mendelian Inheritance in Man (OMIM) websites (accessed 3/ 20/2004) (PubMed, 2004) .
Statistical analyses
As the data were nonparametric, probability analyses were used to evaluate the likelihood of the outcome that one (or more) protein was expressed in one GBM subtype and not the other. The probability that a protein is found in all primary GBMs and none of the secondary GBMs, or vice versa, was calculated using the Mann-Whitney test. Thus, for a given protein, the Mann-Whitney test calculates the probability that a protein would split perfectly between the two groups. The calculated P-value was 0.001166.
Given that there were an estimated 250 proteins found on each gel, it is likely that at least one protein would show a perfect split between the two types. If there is no other, expected difference in any of the 250 proteins, the probability of at least one protein randomly showing a perfect split between two groups is calculated in the following manner: (1-0.001166) 250 , or 0.747015. Using the binomial distribution function, the likelihood that 11 or more proteins would be uniquely expressed in one or the other subtype (that is, the probability that these 11 proteins out of 250 will discriminate perfectly) is given by the binomial probability distribution, which in this case equals approximately 5.5 Â 10 À16 . These probabilities were generated under the assumption that protein expression levels are independent of one another, which, while not likely to be precisely true, does permit an estimation of the likelihood that the unique protein expression patterns, in one subtype of GBM or the other, appears randomly.
